Unmet needs in valvular heart disease
- PMID: 36924203
- DOI: 10.1093/eurheartj/ehad121
Unmet needs in valvular heart disease
Abstract
Valvular heart disease (VHD) is the next epidemic in the cardiovascular field, affecting millions of people worldwide and having a major impact on health care systems. With aging of the population, the incidence and prevalence of VHD will continue to increase. However, VHD has not received the attention it deserves from both the public and policymakers. Despite important advances in the pathophysiology, natural history, management, and treatment of VHD including the development of transcatheter therapies, VHD remains underdiagnosed, identified late, and often undertreated with inequality in access to care and treatment options, and there is no medication that can prevent disease progression. The present review article discusses these gaps in the management of VHD and potential actions to undertake to improve the outcome of patients with VHD.
Keywords: Epidemiology; Intervention; Outcome; Public health; Valvular heart disease.
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest D.M.-Z. has received research grant from Edwards Lifesciences. H.B. received honoraria and travel support from Edwards Lifesciences and Actelion. M.E.-S. received consulting fees from Edwards LLC, Highlife, Artivon, and ChemImage. I.G.B. declares that there is no conflict of interest. A.V. declares that there is no conflict of interest. J.B. has received speaker fees from Edwards Lifesciences and Abbott. P.P. has received funding from Edwards Lifesciences, Medtronic, and Pi-Cardia, for echocardiography core laboratory analyses and research studies in the field of transcatheter valve therapies, for which he received no personal compensation. P.P. has received lecture fees from Edwards Lifesciences and Medtronic. V.C. declares that there is no conflict of interest. M.L. received clinical institutional research grants from Abbott, Boston Scientific, Edwards, and Medtronic. T.M. declares that there is no conflict of interest. B.I. declares that there is no conflict of interest.